丙型肝炎抗病毒治疗后Fibroscan肝硬度与不良结局独立相关
这项回顾性队列研究纳入接受丙型肝炎病毒(HCV)治疗的美国退伍军人,评估治疗前(n=492)或治疗后(n=877)肝硬度与失代偿期肝硬化、肝细胞癌(HCC)或死亡的关系。多变量分析显示,治疗后肝硬度>20 kPa与失代偿期肝硬化(校正HR 3.85,95%CI 1.29-11.50)及复合结局(校正HR 1.95,95%CI 1.07-3.56)独立相关,而治疗前肝硬度与任何结局均无显著关联。
要点
- 治疗后肝硬度>20 kPa者失代偿期肝硬化风险较≤12.5 kPa者升高(校正HR 3.85,95%CI 1.29-11.50)。
- 治疗后肝硬度>20 kPa与死亡、肝移植、失代偿期肝硬化或HCC复合结局独立相关(校正HR 1.95,95%CI 1.07-3.56)。
- 治疗前肝硬度在多变量分析中与任何结局均无显著关联。
核心结论
- 治疗后肝硬度>20 kPa而非治疗前肝硬度,在多变量分析中与失代偿期肝硬化及复合结局独立相关。
- 作者认为应在抗病毒治疗后测量肝硬度,因其可预测不良结局,甚至超越常规可用的临床预测指标。
研究设计与样本
- 回顾性队列研究,纳入开始HCV治疗且治疗前(n=492)或治疗后(n=877)至少有一次肝硬度测量的美国退伍军人。
- 采用Cox比例风险回归,校正年龄、种族/民族、肝硬化病史、体重指数、糖尿病、FIB-4评分、Charlson合并症指数、酒精使用障碍、终末期肝病模型评分及持续病毒学应答状态。
主要发现
- 治疗后肝硬度队列平均随访27.3个月,21例(2.4%)发生失代偿期肝硬化,26例(3.0%)发生HCC,57例(6.5%)死亡或接受肝移植。
- 与治疗后肝硬度≤12.5 kPa者相比,治疗后肝硬度>20 kPa者发生失代偿期肝硬化的校正HR为3.85(95%CI 1.29-11.50)。
- 与治疗后肝硬度≤12.5 kPa者相比,治疗后肝硬度>20 kPa者发生死亡、肝移植、失代偿期肝硬化或HCC复合结局的校正HR为1.95(95%CI 1.07-3.56)。
- 多变量分析中,治疗前肝硬度与任何结局均无显著关联。
临床怎么用
- 作者认为应在抗病毒治疗后测量肝硬度,因其可预测不良结局,甚至超越常规可用的临床预测指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibroscan-derived liver stiffness decreases after anti-viral treatment for hepatitis C virus (HCV) infection, which may affect the associations and interpretation of liver stiffness. AIMS: To assess whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma (HCC) or death. METHODS: In this retrospective cohort study, we identified US veterans who initiated HCV treatment and had at least one liver stiffness before (n = 492) or after (n = 877) HCV therapy. We used Cox proportional hazards regression (adjusting for age, race/ethnicity, history of cirrhosis, body mass index, diabetes, FIB-4 score, Charlson comorbidity index, alcohol use disorder, Model for end-stage liver disease score and sustained virological response status) to determine the associations between pre- or post-treatment liver stiffness values and the development of decompensated cirrhosis, HCC, death or liver transplant. RESULTS: In the post-treatment liver stiffness cohort, during a mean follow-up of 27.3 months, 21 (2.4%) developed decompensated cirrhosis, 26 (3.0%) developed HCC and 57 (6.5%) died or underwent liver transplant. Compared to patients with post-treatment liver stiffness ≤12.5 kPa, those with post-treatment liver stiffness >20 kPa, had higher rates of developing decompensated cirrhosis (adjusted HR 3.85, 95% CI 1.29-11.50) and the composite outcome of death, liver transplant, decompensated cirrhosis or HCC (adjusted HR 1.95, 95% CI: 1.07-3.56). There were no significant associations between pre-treatment liver stiffness and any outcomes on multivariable analysis. CONCLUSIONS: Post-treatment liver stiffness >20 kPa, but not pre-treatment liver stiffness, was independently associated with the development of decompensated cirrhosis and the composite outcome in multivariable analyses. Measuring liver stiffness should be considered after anti-viral treatment because it predicts adverse outcomes even beyond routinely available clinical predictors.
引用
- Vutien P, Kim NJ, Moon AM, et al. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. Aliment Pharmacol Ther. 2020. PMID: 32951216. doi:10.1111/apt.16092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。